ASH: Roche un­corks eye­pop­ping re­spons­es in bis­pe­cif­ic test, hop­ing to add a jew­el to its fu­ture port­fo­lio

In a heat­ed race with some of phar­ma’s biggest play­ers, Roche’s Genen­tech is look­ing to dri­ve a lead bis­pe­cif­ic an­ti­body pro­gram through the clin­ic against …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.